CEL-SCI Corporation news

   Watch this stock
Showing stories 31 - 40 of about 88   

Articles published

CVM 1.89 +0.09 (4.70%)
price chart
2 Stocks Taking a Gut Shot: CEL-SCI Corporation (CVM), Sunworks, Inc. (SUNW)
CEL-SCI Corporation is maintained at an average hold rating by 1 stock analysts, and there are at least 5.34% of shares outstanding that are currently legally short sold.
CEL-SCI Co. (CVM) Sees Large Decrease in Short Interest  Week Herald
Lookout for Price Target? GTx, Inc. (GTXI), CEL-SCI Corporation (CVM)
The average of this ratio is -6.74 for the industry and sector's best figure appears -4.71. CEL-SCI Corporation (NYSE:CVM), at its latest closing price of $0.08, it has a price-to-book ratio of 0.00, compared to an industry average at 18.73.
CEO Geert Kersten Summarizes CEL-SCI's Phase 3 Cancer Immunotherapy Progress ...
CEL-SCI is also testing Multikine with the U.S. Navy in HIV infected patients with HPV related diseases. CEL-SCI has development partnerships with Teva Pharmaceuticals, Orient EuroPharma of Taiwan, Ergomed and the NIH.
Is CEL-SCI Corporation (NYSEMKT:CVM) in Danger of Delisting?
CEL-SCI Corporation (NYSEMKT:CVM) shares dipped 1.17% on Friday to $0.119 and flat in after-hours trading. The company has a market cap of $22.30 million at 190.22 million shares outstanding.
Cel-Sci says arbitration with inVentiv nearing an end
The arbitration relates to a Phase III trial of Cel-Sci's candidate immunotherapy Multikine (Leukocyte Interleukin, Injection) in the treatment of patients suffering squamous cell carcinoma of the head and neck.
CEL-SCI Corp (CVM) Received Incomplete Response To Hold Letter from FDA
CEL-SCI Corp (NYSE: CVM) disclosed that on December 16, 2016, FDA issued an Incomplete Response To Hold letter to us indicating that based on the Agency's preliminary review of our November 18, 2016 submission, FDA has determined that it is not a ...
CEL-SCI Working with FDA to Lift Hold on Phase 3 Trial of Multikine for Head ...
CEL-SCI Corp. has received the official minutes from its Type A (face-to-face) meeting with the U.S. Food and Drug Administration (FDA) concerning the partial clinical hold placed on a Phase 3 trial assessing Multikine (leukocyte interleukin, injection ...
Analyst's Consensus to Hold Signal: CEL-SCI Corporation (CVM)
CEL-SCI Corporation (CVM) stock price traded with surging change along with the volume 0.1 million shares in Friday trading session.
CEL-SCI Corp's (CVM) Multikine Phase 3 Trial Receives FDA Clinical Hold
CEL-SCI Corporation (NYSE: CVM) announced that it has received verbal notice from the U.S. Food and Drug Administration (FDA) that its Multikine (Leukocyte Interleukin Injection) Phase 3 clinical trial in advanced primary head and neck cancer has been ...
Let's Take Some Time To Look Back: Calpine Corporation (CPN), CEL-SCI ...
The company during the last trade was able to reach a volume of 0.85 million shares. That activity is comparable to their recent volume average trend of nearly 0.18 million shares which they recorded over a period of three months.
Stock is Neither buy nor sell: CEL-SCI Corporation (CVM)  Street Observer (press release)
What's Next for Cel Sci Corporation (NYSEAMERICAN:CVM) After Having Less ...  BZ Weekly